Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Use of the novel atypical opioid tapentadol in goats (Capra hircus): Pharmacokinetics after intravenous, and intramuscular administration
Year:
2014
Authors :
Mabjeesh, Sameer Jermaya
;
.
Volume :
37
Co-Authors:
Lavy, E., School of Veterinary Medicine,, The Robert H. Smith Faculty of Agriculture,, Hebrew University of Jerusalem, Rehovot, Israel
Lee, H.-K., College of Veterinary Medicine, Chungnam National University, Daejeon, South Korea
Mabjeesh, S.J., Department of Animal Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, Hebrew University of Jerusalem, Rehovot, Israel
Sabastian, C., Department of Animal Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, Hebrew University of Jerusalem, Rehovot, Israel
Baker, Y., School of Veterinary Medicine,, The Robert H. Smith Faculty of Agriculture,, Hebrew University of Jerusalem, Rehovot, Israel
Giorgi, M., Department of Veterinary Sciences, University of Pisa, Pisa, Italy
Facilitators :
From page:
518
To page:
521
(
Total pages:
4
)
Abstract:
The objective of the present study was to assess the pharmacokinetics of the novel atypical drug tapentadol (TAP) after intravenous (I.V.) and intramuscular (I.M.) injections in clinically healthy goats. A 2 9 2 cross-over design study was carried out. Six local adult Nubian nonlactating, nonpregnant female goats, were given 5 mg/kg body weight of TAP by I.V. and I.M. routes. The concentrations of TAP in plasma were evaluated using a validated HPLC method. Transient adverse effects were noticed in some animals, especially after I.V. administration (tremors and ataxia). Three days after drug administration, severe hair loss was also recorded. The plasma concentrations after the two routes of administration were best described by a bi-compartmental model. After I.M. injection, TAP showed a very fast absorption (Tmax = 0.17 h) and a short half-life (1.29 h). The I.M. bioavailability was quite high, despite being variable (87.8±35.6%). This is the first pharmacokinetic study of TAP in goats but due to its unknown safety profile and efficacy, it is premature to recommend the use of this drug in clinical ovine practice. ©2014 John Wiley and Sons Ltd.
Note:
Related Files :
adult
Animal
Animals
Blood
drug absorption
Drug Safety
Female
goats
metabolism
phenols
Show More
Related Content
More details
DOI :
Article number:
Affiliations:
Database:
Scopus
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
31031
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 00:59
Scientific Publication
Use of the novel atypical opioid tapentadol in goats (Capra hircus): Pharmacokinetics after intravenous, and intramuscular administration
37
Lavy, E., School of Veterinary Medicine,, The Robert H. Smith Faculty of Agriculture,, Hebrew University of Jerusalem, Rehovot, Israel
Lee, H.-K., College of Veterinary Medicine, Chungnam National University, Daejeon, South Korea
Mabjeesh, S.J., Department of Animal Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, Hebrew University of Jerusalem, Rehovot, Israel
Sabastian, C., Department of Animal Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, Hebrew University of Jerusalem, Rehovot, Israel
Baker, Y., School of Veterinary Medicine,, The Robert H. Smith Faculty of Agriculture,, Hebrew University of Jerusalem, Rehovot, Israel
Giorgi, M., Department of Veterinary Sciences, University of Pisa, Pisa, Italy
Use of the novel atypical opioid tapentadol in goats (Capra hircus): Pharmacokinetics after intravenous, and intramuscular administration
The objective of the present study was to assess the pharmacokinetics of the novel atypical drug tapentadol (TAP) after intravenous (I.V.) and intramuscular (I.M.) injections in clinically healthy goats. A 2 9 2 cross-over design study was carried out. Six local adult Nubian nonlactating, nonpregnant female goats, were given 5 mg/kg body weight of TAP by I.V. and I.M. routes. The concentrations of TAP in plasma were evaluated using a validated HPLC method. Transient adverse effects were noticed in some animals, especially after I.V. administration (tremors and ataxia). Three days after drug administration, severe hair loss was also recorded. The plasma concentrations after the two routes of administration were best described by a bi-compartmental model. After I.M. injection, TAP showed a very fast absorption (Tmax = 0.17 h) and a short half-life (1.29 h). The I.M. bioavailability was quite high, despite being variable (87.8±35.6%). This is the first pharmacokinetic study of TAP in goats but due to its unknown safety profile and efficacy, it is premature to recommend the use of this drug in clinical ovine practice. ©2014 John Wiley and Sons Ltd.
Scientific Publication
נגישות
menu      
You may also be interested in